| Today’s Big NewsMar 12, 2024 |
| By Fraiser Kansteiner Despite Moderna’s efforts to prove its mRNA thesis beyond COVID-19 in 2023, the post-pandemic hangover took a heavy toll on the company. In turn, much of the company’s top brass—including CEO Stéphane Bancel—saw their total compensation fall for the year. |
|
|
|
By Annalee Armstrong With 99% of patients experiencing an adverse event, the FDA is skeptical that the risks associated with Geron’s myelodysplastic syndromes medicine imetelstat outweigh the potential benefit of treatment, particularly in patients with lower-risk cases of the blood cancer. |
By Ben Adams Pharma upped its Oscars spending bill this year but there was a noticeable absence from the dominant theme we saw during 2023’s awards night. |
By Conor Hale Once slated to either strike out on their own or be the subject of a potential sale, Medtronic’s patient monitoring and respiratory intervention divisions will see new life after merging into a single multibillion-dollar arm dubbed Acute Care and Monitoring. Fierce Medtech spoke with the unit's president, Frank Chan, about where the division is headed. |
|
Wednesday, March 27, 2024 | 10am ET / 7am PTThere can be numerous challenges encountered during biopharmaceutical process development. Join usfor an important look at formulation development specifically. Featuring real-world examples, this insightful discussion will explore key challenges, as well as the latest techniques and solutions for effectively overcoming current obstacles. Register now.
|
|
By Max Bayer Merck is signing onto a new research and licensing deal with Pearl Bio, offering up to $1 billion in biobucks. The biotech is looking at fusing synthetic chemistry with biologics, broadening its therapeutic capabilities. |
By Gabrielle Masson The FDA isn’t going as far to say that amyloid reduction can be considered a primary endpoint in Alzheimer’s disease trials, but the agency is suggesting that the measure can serve as a surrogate endpoint for predicting clinical benefit. |
By Kevin Dunleavy Taking over as CEO for an aging company in dire financial straits and in need of a slimdown was a challenging assignment for Christophe Bourdon. Under Bourdon’s watch, Leo Pharma is taking steps toward a rebound. Last month, the 115-year-old Danish private company reported that it cut its operating costs by 14% in 2023 while increasing its revenues by 7%. |
By Conor Hale The recall covers 1,500 of the tablet apps used to control its implanted LVAD systems, after eight injuries related to the pumps stopping or starting unexpectedly. |
By Angus Liu The antibody-drug conjugate Adcetris has given Pfizer’s oncology department its first pivotal trial win from the legacy Seagen portfolio since the $43 billion merger. |
By Andrea Park Marketing cut a bigger slice of the budgetary pie at life sciences companies in 2023, a recent survey has found. |
By Max Bayer Eli Lilly is launching back into space for another round of experiments, after taking its first flight in late 2023. The focus of the new voyage is experimenting with chronic disease drug discovery. |
By Nick Paul Taylor The Leukemia & Lymphoma Society (LLS) has a new top sponsor for its Light The Night events. BeiGene has inked a three-year deal for the sponsorship opportunity, bumping AbbVie’s Pharmacyclics and Johnson & Johnson’s Janssen out of the way in the process. |
By Zoey Becker The company will not conduct any further clinical trials of the drug, which is currently approved to treat Parkinson’s disease psychosis. The decision comes after years of failed expansion bids in other uses. |
By Conor Hale After it filed for bankruptcy early last month, the life science tool developer NanoString may have found a new home for its portfolio with the investment firm Patient Square Capital. |
By Ben Adams How do you market a drug for a disease that will make most people squirm? Well, Tarsus isn’t shying away from the topic and is going all out on its new campaign aimed at a condition caused by a skin crawling culprit. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15. |
|
|---|
|
|
|
Monday, April 22, 2024 | 10am ET / 7am PTExplore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now!
|
|
| WhitepaperExplore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
| Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
